Open Widget Area


Research showed Trasylol doubled the risk of death versus the alternatives

In 1993, the FDA approved the use of Trasylol (also known as aprotinin), a drug manufactured by Bayer Pharmaceuticals that is used to reduce bleeding and blood clotting in patients during heart surgery.

In the May 29, 2008 issue of the New England Journal of Medicine (May 29, 2008), the results from the Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) study were released. The BART study is the first head-to-head comparison between Trasylol and two other alternative drugs that surgeons use to reduce bleeding. The study noted a significant absolute increase of 2.1%, or a relative increase of 54%, in the number of deaths in the Trasylol group compared to the alternatives. The cause of death for these patients included kidney failure, heart attack, and stroke.

The authors of the BART study terminated it early due to ethical concerns raised after the research showed that Trasylol doubled the risk of death versus the alternatives. According to lead researcher Dean A. Ferguson, “There was no way we could ethically enroll more patients in the trial because we had our answer.” An accompanying editorial to the study stated that “in all likelihood, this is the end of the aprotinin story.”

After the initial reports were given to the Food & Drug Administration (FDA) in November of 2007, Bayer agreed to temporarily suspend sales and marketing of Trasylol until the BART findings were finalized. Bayer has now notified the FDA that it will begin removing the remaining Trasylol stock in the U.S. Market from hospitals, warehouses and physicians’ supplies.

Side effects of Trasylol include the following:

  • Difficulty breathing or shortness of breath
  • Fast heart beat
  • Nausea and vomiting
  • Skin rash, irritation or inflammation
  • Sudden or severe pain in the chest, legs, head or groin
  • Swelling of the face, lips, tongue or neck

Free Consultation

Reyes | Browne | Reilley has filed numerous cases on behalf of victims and their families against Bayer for their role in the manufacture and use of this dangerous, potentially lethal drug. If you believe you or someone you care about has been damaged, or has died due to a Trasylol injection given during heart surgery, please fill out our Case Review Contact Form to the right on this page for a free consultation.


Reyes | Browne | Reilley Privacy Policy

We provide this privacy statement for the benefit of our website users, consistent with our commitment to privacy.

Your contact information is 100% confidential and secure.

Reyes | Browne | Reilley will keep any and all information collected at this site strictly confidential and will not sell, rent, lend, or exchange that information or otherwise use it in any way to which you have not consented.

All communications with Reyes | Browne | Reilley are completely confidential.

When you speak to an attorney, everything you say is confidential. Our communications with you are absolutely private, always. We never discuss the details of your circumstances with anyone without your express permission.


Submission of the contact form does not form an attorney-client relationship, however. An attorney-client relationship with Reyes | Browne | Reilley will be formed only if and when you sign a retainer agreement with our firm. Nevertheless, the (non)existence of an attorney-client relationship will not effect the complete confidentiality of your information submitted through this website.

Absolutely free consultation, plus...

Along with free consultation, we offer free information kits, brochures, and videos to help you better understand your situation. We’ll even sign you up for our monthly emailed newsletter, which provides up-to-date information about the product that harmed you and any litigation involving it.

Unsubscribing is easy.

You always have the option to immediately unsubscribe from any and all newsletters (or other mailing lists) by following a link included in every email newsletter sent. We’ll be sorry to see you go, but, after submitting a contact form, if you ever advise Reyes | Browne | Reilley by any means (including but not limited to mail, email, telephone, or fax) that you do not wish to be contacted further, you will not be contacted further by us.